BR112021019204A2 - Inibidores da proteína quinase c atípica e o uso dos mesmos no tratamento de cânceres dependente da via de hedgehog - Google Patents
Inibidores da proteína quinase c atípica e o uso dos mesmos no tratamento de cânceres dependente da via de hedgehogInfo
- Publication number
- BR112021019204A2 BR112021019204A2 BR112021019204A BR112021019204A BR112021019204A2 BR 112021019204 A2 BR112021019204 A2 BR 112021019204A2 BR 112021019204 A BR112021019204 A BR 112021019204A BR 112021019204 A BR112021019204 A BR 112021019204A BR 112021019204 A2 BR112021019204 A2 BR 112021019204A2
- Authority
- BR
- Brazil
- Prior art keywords
- hedgehog pathway
- protein kinase
- inhibitors
- treatment
- dependent
- Prior art date
Links
- 241000289669 Erinaceus europaeus Species 0.000 title abstract 6
- 230000037361 pathway Effects 0.000 title abstract 6
- 230000001419 dependent effect Effects 0.000 title abstract 5
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- 101710082924 Atypical protein kinase C Proteins 0.000 title abstract 2
- 229940123924 Protein kinase C inhibitor Drugs 0.000 title abstract 2
- 239000003881 protein kinase C inhibitor Substances 0.000 title abstract 2
- 206010027476 Metastases Diseases 0.000 abstract 1
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 abstract 1
- 230000005907 cancer growth Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 230000009401 metastasis Effects 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 239000003909 protein kinase inhibitor Substances 0.000 abstract 1
- 230000011664 signaling Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
inibidores da proteína quinase c atípica e o uso dos mesmos no tratamento de cânceres dependente da via de hedgehog. métodos para o tratamento de cânceres dependentes da via de hedgehog são fornecidos. aspectos dos métodos incluem a inibição do crescimento, proliferação ou metástase de câncer dependente da via de hedgehog que é promovida pela sinalização da via de hedgehog. em particular, são divulgados métodos de tratamento de cânceres dependentes da via de hedgehog com inibidores da proteína quinase c iota atípica
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962825334P | 2019-03-28 | 2019-03-28 | |
| PCT/US2020/025437 WO2020198670A1 (en) | 2019-03-28 | 2020-03-27 | Inhibitors of atypical protein kinase c and their use in treating hedgehog pathway-dependent cancers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021019204A2 true BR112021019204A2 (pt) | 2021-11-30 |
Family
ID=72611927
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021019204A BR112021019204A2 (pt) | 2019-03-28 | 2020-03-27 | Inibidores da proteína quinase c atípica e o uso dos mesmos no tratamento de cânceres dependente da via de hedgehog |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220143028A1 (pt) |
| EP (1) | EP3947380A4 (pt) |
| JP (1) | JP2022527320A (pt) |
| KR (1) | KR20220002930A (pt) |
| CN (1) | CN114206865A (pt) |
| AU (1) | AU2020248096A1 (pt) |
| BR (1) | BR112021019204A2 (pt) |
| CA (1) | CA3135196A1 (pt) |
| IL (1) | IL286699A (pt) |
| MX (1) | MX2021011788A (pt) |
| SG (1) | SG11202110270YA (pt) |
| WO (1) | WO2020198670A1 (pt) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9073964B2 (en) * | 2011-05-06 | 2015-07-07 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibitors of atypical protein kinase C and their use in treating hedgehog pathway-dependent cancers |
| MX2015004016A (es) * | 2012-09-28 | 2016-02-18 | Ignyta Inc | Inhibidores de azaquinazolina de la proteina quinasa c atipica. |
| US9192609B2 (en) * | 2013-04-17 | 2015-11-24 | Hedgepath Pharmaceuticals, Inc. | Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors |
| TWI675836B (zh) * | 2014-03-25 | 2019-11-01 | 美商伊格尼塔公司 | 非典型蛋白質激酶ｃ之氮雜喹唑啉抑制劑 |
| EP3665482A4 (en) * | 2017-08-11 | 2021-06-30 | Board Of Regents, The University Of Texas System | TARGETING KINASES FOR THE TREATMENT OF CARCINOUS METASTASES |
-
2020
- 2020-03-27 CA CA3135196A patent/CA3135196A1/en active Pending
- 2020-03-27 EP EP20779899.2A patent/EP3947380A4/en active Pending
- 2020-03-27 KR KR1020217035054A patent/KR20220002930A/ko unknown
- 2020-03-27 MX MX2021011788A patent/MX2021011788A/es unknown
- 2020-03-27 SG SG11202110270YA patent/SG11202110270YA/en unknown
- 2020-03-27 CN CN202080039400.7A patent/CN114206865A/zh active Pending
- 2020-03-27 US US17/598,719 patent/US20220143028A1/en active Pending
- 2020-03-27 BR BR112021019204A patent/BR112021019204A2/pt unknown
- 2020-03-27 JP JP2021558519A patent/JP2022527320A/ja active Pending
- 2020-03-27 WO PCT/US2020/025437 patent/WO2020198670A1/en unknown
- 2020-03-27 AU AU2020248096A patent/AU2020248096A1/en active Pending
-
2021
- 2021-09-26 IL IL286699A patent/IL286699A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022527320A (ja) | 2022-06-01 |
| EP3947380A1 (en) | 2022-02-09 |
| WO2020198670A1 (en) | 2020-10-01 |
| SG11202110270YA (en) | 2021-10-28 |
| EP3947380A4 (en) | 2023-01-11 |
| AU2020248096A1 (en) | 2021-10-14 |
| WO2020198670A9 (en) | 2020-11-19 |
| IL286699A (en) | 2021-12-01 |
| CA3135196A1 (en) | 2020-10-01 |
| CN114206865A (zh) | 2022-03-18 |
| MX2021011788A (es) | 2022-01-24 |
| US20220143028A1 (en) | 2022-05-12 |
| KR20220002930A (ko) | 2022-01-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2023000972A1 (es) | Inhibidores de ras | |
| CY1121831T1 (el) | Παραγωγα θειενο [2,3-c] πυρρολ-4-ονης ως αναστολεις της erk | |
| BR112016017700A2 (pt) | método para tratamento de um câncer em um indivíduo, medicamento, kit, método, uso ou kit, e, método, medicamento ou kit | |
| MX2019007243A (es) | Inhibidores de ectonucleotidasa y metodos de uso de los mismos. | |
| MX2018005600A (es) | Composiciones farmaceuticas y metodos para la inhibicion de indolamina 2,3-dioxigenasa e indicaciones para ello. | |
| CY1122243T1 (el) | Παραγωγα ν-πυριδiνυλικoυ ακεταμιδιου ως αναστολεις της οδου σηματοδοτησης wnt | |
| MX2016016364A (es) | Terapia de combinacion con inhibidores de glutaminasa. | |
| MX2020013320A (es) | Inhibidores de ectonucleotidasa y métodos de uso de los mismos. | |
| BR112017019738A2 (pt) | macrociclos peptidomiméticos e usos dos mesmos | |
| MX2022008868A (es) | Tratamiento del cancer con tg02. | |
| BR112018075135A2 (pt) | combinações farmacêuticas para tratar câncer | |
| AU2016304856A8 (en) | Mechanism of resistance to BET bromodomain inhibitors | |
| EA201991091A1 (ru) | Способы лечения пациентов со злокачественными новообразованиями с применением ингибиторов фарнезилтрансферазы | |
| SG11201907581VA (en) | Hexokinase 2-specific inhibitors for use in acute central nervous system injury | |
| MX2019002108A (es) | Terapia de combinacion con inhibidores de glutaminasa. | |
| BR112021020226A2 (pt) | Inibidores de via de sinalização notch e uso dos mesmos no tratamento de cânceres | |
| AR119934A1 (es) | Inhibidores de pikfyve para terapia contra el cáncer | |
| BR112022011998A2 (pt) | Usos de anticorpos anti-tgfss e inibidores de checkpoint para o tratamento de doenças proliferativas | |
| BR112017026201A2 (pt) | inibidores de mir-155 para o tratamento de linfoma cutâneo de células t (ctcl) | |
| MX2022006932A (es) | Combinaciones de inhibidores de diacilglicerol cinasas (dgk) y antagonistas de puntos de control. | |
| BR112017018198A2 (pt) | inibição da atividade de olig2 | |
| BR112022007179A2 (pt) | Inibidores de tim-3 e usos dos mesmos | |
| ZA201901367B (en) | Inhibition of olig2 activity | |
| BR112018005331A2 (pt) | inibidores de pcna | |
| WO2018102766A9 (en) | Small molecule bcl-2 functional converters as cancer therapeutics |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B15K | Others concerning applications: alteration of classification |
Free format text: AS CLASSIFICACOES ANTERIORES ERAM: C07D 471/04 , C07D 493/08 , C07D 498/04 Ipc: A61K 31/167 (2006.01), A61K 31/519 (2006.01), A61K |